Relationship of visceral adipose tissue with surrogate insulin resistance and liver markers in individuals with metabolic syndrome chronic complications.
insulin resistance
metabolic syndrome
non-alcoholic fatty liver disease
triglyceride glucose index
visceral adipose tissue
Journal
Therapeutic advances in endocrinology and metabolism
ISSN: 2042-0188
Titre abrégé: Ther Adv Endocrinol Metab
Pays: United States
ID NLM: 101532143
Informations de publication
Date de publication:
2020
2020
Historique:
received:
28
05
2020
accepted:
20
08
2020
entrez:
5
11
2020
pubmed:
6
11
2020
medline:
6
11
2020
Statut:
epublish
Résumé
Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS). A cross-sectional study was performed including 326 participants with MetS (55-75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT ( Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1-10.7) had a positive association with HOMA-IR [ A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.
Sections du résumé
BACKGROUND
BACKGROUND
Visceral adipose tissue (VAT) has a hazardous influence on systemic inflammation, insulin resistance and an adverse metabolic profile, which increases the risk of developing non-alcoholic fatty liver disease (NAFLD) and chronic complications of diabetes. In our study we aimed to evaluate the association of VAT and the triglyceride glucose (TyG) as a proxy of insulin resistance surrogated with metabolic and liver risk factors among subjects diagnosed with metabolic syndrome (MetS).
METHODS
METHODS
A cross-sectional study was performed including 326 participants with MetS (55-75 years) from the PREDIMED-Plus study. Liver-status markers, VAT and TyG were assessed. Participants were stratified by tertiles according to VAT (
RESULTS
RESULTS
Subjects with greater visceral fat depots showed worse lipid profile, higher homeostatic model assessment for insulin resistance (HOMA-IR), TyG, alanine transaminase (ALT), fibroblast growth factor-21 (FGF-21), fatty liver index (FLI) and hepatic steatosis index (HSI) compared with participants in the first tertile. The multi-adjusted linear-regression analyses indicated that individuals in the third tertile of TyG (>9.1-10.7) had a positive association with HOMA-IR [
CONCLUSIONS
CONCLUSIONS
A disrupted VAT enlargement and impairment of TyG are strongly associated with liver status and cardiometabolic risk factors linked with NAFLD in individuals diagnosed with MetS. Moreover, the TyG could be used as a suitable and reliable marker estimator of VAT.
Identifiants
pubmed: 33149882
doi: 10.1177/2042018820958298
pii: 10.1177_2042018820958298
pmc: PMC7586032
doi:
Types de publication
Journal Article
Langues
eng
Pagination
2042018820958298Informations de copyright
© The Author(s), 2020.
Déclaration de conflit d'intérêts
Conflict of interest statement: The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Références
PLoS One. 2017 Sep 28;12(9):e0185403
pubmed: 28957363
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304
pubmed: 19067533
World J Gastroenterol. 2019 Mar 21;25(11):1307-1326
pubmed: 30918425
Nutrients. 2017 Apr 14;9(4):
pubmed: 28420094
PLoS One. 2017 Oct 27;12(10):e0187066
pubmed: 29077769
Obes Sci Pract. 2017 Mar;3(1):106-114
pubmed: 28392937
World J Gastroenterol. 2007 Jul 14;13(26):3540-53
pubmed: 17659704
Br J Nutr. 2010 Jun;103(12):1808-16
pubmed: 20102675
Cardiovasc Diabetol. 2013 Aug 28;12:124
pubmed: 23981342
J Hepatol. 2019 Mar;70(3):531-544
pubmed: 30414863
J Hepatol. 2016 Sep;65(3):643-4
pubmed: 27401791
Cell Metab. 2015 May 5;21(5):739-46
pubmed: 25955209
Biol Sex Differ. 2012 May 31;3(1):13
pubmed: 22651247
Nutrition. 2020 Mar;71:110620
pubmed: 31838461
Medicine (Baltimore). 2015 Dec;94(48):e2159
pubmed: 26632897
Ageing Res Rev. 2009 Oct;8(4):339-48
pubmed: 19576300
Cardiovasc Diabetol. 2014 Oct 20;13:146
pubmed: 25326814
Front Endocrinol (Lausanne). 2015 Sep 23;6:147
pubmed: 26441837
Obesity (Silver Spring). 2012 May;20(5):1109-14
pubmed: 22240726
Womens Health (Lond). 2009 Mar;5(2):191-203
pubmed: 19245356
Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20
pubmed: 28930295
Appl Physiol Nutr Metab. 2008 Aug;33(4):784-90
pubmed: 18641723
BMC Med. 2014 Sep 10;12:154
pubmed: 25204761
JAMA. 2019 Oct 15;322(15):1486-1499
pubmed: 31613346
Ther Adv Endocrinol Metab. 2011 Oct;2(5):211-25
pubmed: 23148186
Clin Nutr. 2019 Jun;38(3):1324-1331
pubmed: 29910068
Circulation. 2009 Oct 20;120(16):1640-5
pubmed: 19805654
Nat Rev Dis Primers. 2017 Jun 15;3:17034
pubmed: 28617414
Lipids Health Dis. 2018 Nov 20;17(1):262
pubmed: 30458848
Hepatology. 2018 Jan;67(1):328-357
pubmed: 28714183
Curr Opin Clin Nutr Metab Care. 2016 Jan;19(1):5-11
pubmed: 26560521
JAMA. 2015 Jun 9;313(22):2263-73
pubmed: 26057287
J Nutr. 2011 Jun;141(6):1140-5
pubmed: 21508208
Aliment Pharmacol Ther. 2014 Nov;40(10):1209-22
pubmed: 25267215
Hepatology. 2019 Aug;70(2):711-724
pubmed: 30556145
Medicine (Baltimore). 2015 Mar;94(9):e573
pubmed: 25738475
J Lipid Res. 2019 Oct;60(10):1710-1719
pubmed: 30097511
Metabolism. 2015 Mar;64(3):380-90
pubmed: 25516477
Lipids Health Dis. 2017 Jan 19;16(1):15
pubmed: 28103934
Eur J Clin Nutr. 2019 Feb;73(2):209-214
pubmed: 30323174
Yonsei Med J. 2017 Jan;58(1):158-164
pubmed: 27873509
Public Health Nutr. 2005 Oct;8(7):920-7
pubmed: 16277809
J Korean Med Sci. 2017 Mar;32(3):427-433
pubmed: 28145645
Life Sci. 2016 Mar 1;148:183-93
pubmed: 26851532
Dig Liver Dis. 2010 Jul;42(7):503-8
pubmed: 19766548
Diabetes Care. 2014 Jan;37 Suppl 1:S14-80
pubmed: 24357209
Diabetes. 2011 Jun;60(6):1660-7
pubmed: 21521874
BMC Gastroenterol. 2006 Nov 02;6:33
pubmed: 17081293
Int J Med Sci. 2019 Jan 1;16(1):75-83
pubmed: 30662331
J Cardiovasc Pharmacol Ther. 2005 Mar;10(1):45-54
pubmed: 15821838
J Clin Invest. 2004 Jun;113(11):1582-8
pubmed: 15173884
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Int J Epidemiol. 2019 Apr 1;48(2):387-388o
pubmed: 30476123
Metab Syndr Relat Disord. 2019 Sep;17(7):362-366
pubmed: 31188051
Hepatobiliary Surg Nutr. 2020 Jun;9(3):379-381
pubmed: 32509835
Prev Med. 2016 May;86:99-105
pubmed: 26854766
PLoS One. 2017 Jan 13;12(1):e0168148
pubmed: 28085886